Highlights Newsletter 3
This newsletter presents you the following key sessions:
3. Asciminib as a new treatment option in later-line chronic myeloid leukaemia in chronic phase
This newsletter presents you the following key sessions:
3. Asciminib as a new treatment option in later-line chronic myeloid leukaemia in chronic phase
Medical writer
Medical writer